Page last updated: 2024-08-24

gemcitabine and binimetinib

gemcitabine has been researched along with binimetinib in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Abu-Suboh, M; Allende, E; Arribas, J; Balsells, J; Bernadó Morales, C; Bilal, F; Carreras, MJ; Macarulla, T; Massó-Vallés, D; Mohan, V; Pedersen, K; Sagi, I; Salcedo, MT; Serres, X; Soucek, L; Tabernero, J; Vivancos, A	1
Abou-Alfa, GK; Berger, M; Bradley, M; Capanu, M; Cercek, A; Chou, JF; Dika, IE; Gerst, S; Harding, JJ; Hollywood, E; Lowery, MA; Morgono, E; O'Reilly, EM; Ptashkin, R; Rasalan-Ho, T; Salehi, E; Valentino, E; Wong, P; Yu, KH; Zehir, A	1

Trials

1 trial(s) available for gemcitabine and binimetinib

Article	Year
Binimetinib plus Gemcitabine and Cisplatin Phase I/II Trial in Patients with Advanced Biliary Cancers. Clinical cancer research : an official journal of the American Association for Cancer Research, 2019, 02-01, Volume: 25, Issue:3 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; MAP Kinase Signaling System; Middle Aged; Mutation; Proto-Oncogene Proteins B-raf	2019

Article

Year

Binimetinib plus Gemcitabine and Cisplatin Phase I/II Trial in Patients with Advanced Biliary Cancers.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2019, 02-01, Volume: 25, Issue:3

Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; MAP Kinase Signaling System; Middle Aged; Mutation; Proto-Oncogene Proteins B-raf

2019

Other Studies

1 other study(ies) available for gemcitabine and binimetinib

Article	Year
Pancreatic cancer heterogeneity and response to Mek inhibition. Oncogene, 2017, 10-05, Volume: 36, Issue:40 Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; DNA Methylation; DNA, Neoplasm; Drug Resistance, Neoplasm; Female; Gemcitabine; Genetic Heterogeneity; Humans; Mice, Inbred BALB C; Mice, Inbred NOD; Mice, SCID; Mitogen-Activated Protein Kinase Kinases; Mutation; Paclitaxel; Pancreatic Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Xenograft Model Antitumor Assays	2017

Article

Year

Pancreatic cancer heterogeneity and response to Mek inhibition.

Oncogene, 2017, 10-05, Volume: 36, Issue:40

Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; DNA Methylation; DNA, Neoplasm; Drug Resistance, Neoplasm; Female; Gemcitabine; Genetic Heterogeneity; Humans; Mice, Inbred BALB C; Mice, Inbred NOD; Mice, SCID; Mitogen-Activated Protein Kinase Kinases; Mutation; Paclitaxel; Pancreatic Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Xenograft Model Antitumor Assays

2017